应交易所要求,美/港股行情延时15分钟展示,下载APP即可免费查看实时行情。
关闭
02607 上海医药
午间休市 04-19 12:35:15
10.840
+0.060
+0.56%
最高
10.920
最低
10.680
成交量
68.32万
今开
10.780
昨收
10.780
日振幅
2.23%
总市值
401.44亿
流通市值
99.63亿
总股本
37.03亿
成交额
737.99万
换手率
0.07%
流通股本
9.19亿
市净率
--
ROE
--
每股收益
0.00
52周最高
--
52周最低
--
市盈率
--
股息
--
股息收益率
--
ROA
--
分时
五日
日K
周K
月K
北京优虎网络科技有限公司
免责声明:香港交易所资讯服务有限公司、其控股公司及/或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度,但不能保证其绝对准确和可靠,且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任(不管是否侵权法下的责任或合约责任又或其它责任)
资讯
新帖
简况
大摩:予上海医药(02607)“增持”评级 目标价降至17港元
智通财经网 · 10:43
大摩:予上海医药(02607)“增持”评级 目标价降至17港元
上海医药04月18日主力资金流入194万元 连续5日加仓
自选股智能写手 · 04-18 16:15
上海医药04月18日主力资金流入194万元 连续5日加仓
瑞银:首予上海医药(02607)“买入”评级 目标价14.9港元
智通财经网 · 04-17 14:07
瑞银:首予上海医药(02607)“买入”评级 目标价14.9港元
上海医药(02607.HK)4月26日举行董事会会议批准一季度业绩
格隆汇资讯 · 04-16 16:42
上海医药(02607.HK)4月26日举行董事会会议批准一季度业绩
上海医药04月16日主力资金流入121万元 连续3日加仓
自选股智能写手 · 04-16 16:15
上海医药04月16日主力资金流入121万元 连续3日加仓
【券商聚焦】招银国际料今年中国医药行业有望回归健康增长
金吾财讯 · 04-16 14:56
【券商聚焦】招银国际料今年中国医药行业有望回归健康增长
上海医药(601607)4月15日主力资金净买入1219.82万元
证券之星 · 04-16
上海医药(601607)4月15日主力资金净买入1219.82万元
上海医药:聪明汤为一款中药创新药,目前处在IIT阶段
每日经济新闻 · 04-15
上海医药:聪明汤为一款中药创新药,目前处在IIT阶段
西南证券:给予上海医药买入评级
证券之星 · 04-11
西南证券:给予上海医药买入评级
上海医药(02607):雷贝拉唑钠肠溶片通过仿制药一致性评价
智通财经 · 04-10
上海医药(02607):雷贝拉唑钠肠溶片通过仿制药一致性评价
上海医药:雷贝拉唑钠肠溶片通过仿制药一致性评价
南方财经网 · 04-10
上海医药:雷贝拉唑钠肠溶片通过仿制药一致性评价
上海医药(601607.SH):雷贝拉唑钠肠溶片通过仿制药一致性评价
智通财经 · 04-10
上海医药(601607.SH):雷贝拉唑钠肠溶片通过仿制药一致性评价
上海医药:劳拉西泮片通过仿制药质量和疗效一致性评价
证券日报 · 04-10
上海医药:劳拉西泮片通过仿制药质量和疗效一致性评价
上海医药(02607):劳拉西泮片通过仿制药质量和疗效一致性评价
智通财经网 · 04-09
上海医药(02607):劳拉西泮片通过仿制药质量和疗效一致性评价
上海医药最新公告:控股子公司劳拉西泮片通过仿制药一致性评价
证券之星 · 04-09
上海医药最新公告:控股子公司劳拉西泮片通过仿制药一致性评价
上海医药(601607.SH):劳拉西泮片通过仿制药一致性评价
智通财经 · 04-09
上海医药(601607.SH):劳拉西泮片通过仿制药一致性评价
上海医药04月09日主力资金流入1077万元 连续3日加仓
自选股智能写手 · 04-09
上海医药04月09日主力资金流入1077万元 连续3日加仓
【AH互动】上海医药(02607)涨超7% A股逆向下行 机构料创新药业务迎来收获期
金吾财讯 · 04-08
【AH互动】上海医药(02607)涨超7% A股逆向下行 机构料创新药业务迎来收获期
上海医药(02607)下跌5.02%,报10.6元/股
金融界 · 04-05
上海医药(02607)下跌5.02%,报10.6元/股
上海医药(02607)股价下跌5.018%,现价港币$10.6
阿斯达克财经 · 04-05
上海医药(02607)股价下跌5.018%,现价港币$10.6
加载更多
公司概况
公司名称:
上海医药
所属市场:
SEHK
上市日期:
--
主营业务:
上海医药集团股份有限公司是一家主要从事医药工业、分销与零售业务的中国公司。该公司的产品包括创新药、化学药、中药和罕见病药。该公司的产品主要用于心血管系统、消化道和新陈代谢、全身性抗感染、中枢神经系统、抗肿瘤和免疫调节剂、骨骼肌肉系统和呼吸系统等领域。另外,该公司还提供医药物流和仓储服务。该公司的产品销往中国国内和海外市场。
发行价格:
--
{"stockData":{"symbol":"02607","market":"HK","secType":"STK","nameCN":"上海医药","latestPrice":10.84,"timestamp":1713501315417,"preClose":10.78,"halted":0,"volume":683200,"delay":0,"floatShares":919072704,"shares":3703301054,"eps":1.1000504,"marketStatus":"午间休市","marketStatusCode":3,"change":0.06,"latestTime":"04-19 12:35:15","open":10.78,"high":10.92,"low":10.68,"amount":7379875,"amplitude":0.022263,"askPrice":10.84,"askSize":4100,"bidPrice":10.8,"bidSize":1300,"shortable":3,"etf":0,"ttmEps":1.1000504748443678,"exchange":"SEHK","tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1713502800000},"adr":0,"listingDate":1305820800000,"adjPreClose":10.78,"dividendRate":0.04086,"openAndCloseTimeList":[[1713490200000,1713499200000],[1713502800000,1713513600000]],"volumeRatio":0.646867,"lotSize":100,"spreadScale":0,"tradeCurrency":"HKD","astockBrief":{"symbol":"601607","market":"SH","secType":"STK","nameCN":"上海医药","latestPrice":17.7,"timestamp":1713497398000,"preClose":17.48,"halted":0,"volume":10124300,"delay":0,"premium":"-43.32"}},"requestUrl":"/m/hq/s/02607","defaultTab":"news","newsList":[{"id":"2428350832","title":"大摩:予上海医药(02607)“增持”评级 目标价降至17港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2428350832","media":"智通财经网","top":-1,"share":"https://www.laohu8.com/m/news/2428350832?lang=zh_cn&edition=full","pubTime":"2024-04-19 10:43","pubTimestamp":1713494632,"startTime":"0","endTime":"0","summary":"大摩对海医药(02607)2024-2030年盈利预测下调2%-9%。","market":"hk","thumbnail":"https://img.zhitongcaijing.com/image/20240419/20240419104415_70498.png?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250","type":0,"news_type":0,"thumbnails":["https://img.zhitongcaijing.com/image/20240419/20240419104415_70498.png?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250"],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1105173.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2428420551","title":"上海医药04月18日主力资金流入194万元 连续5日加仓","url":"https://stock-news.laohu8.com/highlight/detail?id=2428420551","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2428420551?lang=zh_cn&edition=full","pubTime":"2024-04-18 16:15","pubTimestamp":1713428120,"startTime":"0","endTime":"0","summary":"04月18日, 上海医药股价涨0.75%,报收10.78元,成交金额2748万元,换手率0.28%,振幅2.99%,量比1.22。上海医药今日主力资金净流入194万元,连续5日净流入,上一交易日主力净流入398万元,今日环比减少51.26%。近一年数据显示,该股主力连续5日净流入后,次日上涨概率为33.33%,平均涨幅为2.44%。该股近5个交易日下跌2.18%,主力资金累计净流入1035万元;近20日主力资金累计净流入4082万元,其中净流入天数为14日。该股主力净额占比0.02%,港股市场排名174/2628。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404181615368b34bc29&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404181615368b34bc29&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2428365895","title":"瑞银:首予上海医药(02607)“买入”评级 目标价14.9港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2428365895","media":"智通财经网","top":-1,"share":"https://www.laohu8.com/m/news/2428365895?lang=zh_cn&edition=full","pubTime":"2024-04-17 14:07","pubTimestamp":1713334066,"startTime":"0","endTime":"0","summary":"瑞银预测上海医药(02607)2024至2026年收入及盈利年均复合增长率可达10%及10.6%。","market":"us","thumbnail":"https://img.zhitongcaijing.com/image/20240417/20240417140800_48796.png?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250","type":0,"news_type":0,"thumbnails":["https://img.zhitongcaijing.com/image/20240417/20240417140800_48796.png?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250"],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1103765.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2427681086","title":"上海医药(02607.HK)4月26日举行董事会会议批准一季度业绩","url":"https://stock-news.laohu8.com/highlight/detail?id=2427681086","media":"格隆汇资讯","top":-1,"share":"https://www.laohu8.com/m/news/2427681086?lang=zh_cn&edition=full","pubTime":"2024-04-16 16:42","pubTimestamp":1713256929,"startTime":"0","endTime":"0","summary":"格隆汇4月16日丨上海医药(02607.HK)宣布,董事会会议将于2024年4月26日(星期五)举行,藉以(其中包括)批准公司及其附属公司截至2024年3月31日止三个月的第一季度业绩及其发布。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240416164218878369e8&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240416164218878369e8&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2427817873","title":"上海医药04月16日主力资金流入121万元 连续3日加仓","url":"https://stock-news.laohu8.com/highlight/detail?id=2427817873","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2427817873?lang=zh_cn&edition=full","pubTime":"2024-04-16 16:15","pubTimestamp":1713255307,"startTime":"0","endTime":"0","summary":"04月16日, 上海医药股价跌2.76%,报收10.56元,成交金额3596万元,换手率0.37%,振幅3.87%,量比1.56。上海医药今日主力资金净流入121万元,连续3日净流入,上一交易日主力净流入178万元,今日环比减少32.02%。近一年数据显示,该股主力连续3日净流入后,次日上涨概率为28.57%,平均涨幅为1.83%。该股近5个交易日下跌5.41%,主力资金累计净流入533万元;近20日主力资金累计净流入3482万元,其中净流入天数为13日。该股主力净额占比0.01%,港股市场排名167/2628。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404161615128b299199&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404161615128b299199&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2427139158","title":"【券商聚焦】招银国际料今年中国医药行业有望回归健康增长","url":"https://stock-news.laohu8.com/highlight/detail?id=2427139158","media":"金吾财讯","top":-1,"share":"https://www.laohu8.com/m/news/2427139158?lang=zh_cn&edition=full","pubTime":"2024-04-16 14:56","pubTimestamp":1713250565,"startTime":"0","endTime":"0","summary":"金吾财讯 | 招银国际表示,年初至今,MSCI中国医疗指数下跌22.7%,跑输MSCI中国指数23.3%。展望2024年,随着行业监管常态化进行,新冠基数影响逐渐消退,中国医药行业有望回归健康增长。另外,行业监管仍呈现持续高压态势,预计院内刚需将在下半年出现需求复苏。该行认为,行业严格监管或将常态化,然而,诊疗秩序逐步正常,院内产品和服务的需求仍将保持健康。考虑到基数原因,该行预期行业或将于今年下半年加速增长。","market":"sh","thumbnail":"https://static.szfiu.com/news/20210810/YjQxYWY4NjkyMTU2YjM4ZTVhNGFhMzYzNjE2NzgxMDU=.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20210810/YjQxYWY4NjkyMTU2YjM4ZTVhNGFhMzYzNjE2NzgxMDU=.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"1935150","is_publish_highlight":false,"gpt_icon":0},{"id":"2427397859","title":"上海医药(601607)4月15日主力资金净买入1219.82万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2427397859","media":"证券之星","top":-1,"share":"https://www.laohu8.com/m/news/2427397859?lang=zh_cn&edition=full","pubTime":"2024-04-16 08:09","pubTimestamp":1713226170,"startTime":"0","endTime":"0","summary":"证券之星消息,截至2024年4月15日收盘,上海医药报收于17.32元,上涨3.59%,换手率1.0%,成交量19.36万手,成交额3.33亿元。近5日资金流向一览见下表:上海医药融资融券信息显示,融资方面,当日融资买入849.82万元,融资偿还3068.22万元,融资净偿还2218.4万元。上海医药主营业务:化学原料药、化学药制剂、抗生素、生化药品、生物制品中成药、医疗器械、制药设备、化学危险物品等的生产、销售及进出口业务。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024041600011478.shtml","is_publish_highlight":false,"gpt_icon":0},{"id":"2427258410","title":"上海医药:聪明汤为一款中药创新药,目前处在IIT阶段","url":"https://stock-news.laohu8.com/highlight/detail?id=2427258410","media":"每日经济新闻","top":-1,"share":"https://www.laohu8.com/m/news/2427258410?lang=zh_cn&edition=full","pubTime":"2024-04-15 16:14","pubTimestamp":1713168865,"startTime":"0","endTime":"0","summary":"有投资者在投资者互动平台提问:公司创新药在研管线,有个项目叫聪明汤,请问这是中药吗?上海医药(601607.SH)4月15日在投资者互动平台表示,聪明汤为一款中药创新药,目前处在IIT阶段。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202404153044573866.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202404153044573866.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2426032664","title":"西南证券:给予上海医药买入评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2426032664","media":"证券之星","top":-1,"share":"https://www.laohu8.com/m/news/2426032664?lang=zh_cn&edition=full","pubTime":"2024-04-11 10:58","pubTimestamp":1712804337,"startTime":"0","endTime":"0","summary":"西南证券股份有限公司杜向阳近期对上海医药进行研究并发布了研究报告《23年收入稳健增长,创新管线步入收获期》,本报告对上海医药给出买入评级,当前股价为16.8元。 上海医药 投资要点事件:公司发布]2023年年报。预计2024-2026年归母净利润分别为54.4亿元、60.1亿元、66.2亿元,分别同增44.3%/10.5%/10.3%,维持“买入”评级。最新盈利预测明细如下:该股最近90天内共有5家机构给出评级,买入评级4家,增持评级1家;过去90天内机构目标均价为22.19。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024041100015231.shtml","is_publish_highlight":false,"gpt_icon":0},{"id":"2426452677","title":"上海医药(02607):雷贝拉唑钠肠溶片通过仿制药一致性评价","url":"https://stock-news.laohu8.com/highlight/detail?id=2426452677","media":"智通财经","top":-1,"share":"https://www.laohu8.com/m/news/2426452677?lang=zh_cn&edition=full","pubTime":"2024-04-10 17:20","pubTimestamp":1712740843,"startTime":"0","endTime":"0","summary":"智通财经APP讯,上海医药 发布公告,近日,该公司全资子公司上海上药信谊药厂有限公司收到国家药品监督管理局颁发的关于雷贝拉唑钠肠溶片的《药品补充申请批准通知书》,该药品通过仿制药一致性评价。2023年9月,上药信谊就该药品仿制药一致性评价向国家药监局提出申请并获受理。截至本公告日,公司针对该药品的一致性评价已投入研发费用约人民币1614万元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1100619.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2426459526","title":"上海医药:雷贝拉唑钠肠溶片通过仿制药一致性评价","url":"https://stock-news.laohu8.com/highlight/detail?id=2426459526","media":"南方财经网","top":-1,"share":"https://www.laohu8.com/m/news/2426459526?lang=zh_cn&edition=full","pubTime":"2024-04-10 16:35","pubTimestamp":1712738127,"startTime":"0","endTime":"0","summary":"南方财经4月10日电,上海医药公告,子公司上药信谊雷贝拉唑钠肠溶片通过仿制药一致性评价。雷贝拉唑钠肠溶片主要用于治疗胃溃疡、十二指肠溃疡、吻合口溃疡、反流性食管炎、卓-艾氏(Zollinger-Ellison)综合征。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202404103039305732.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2426456951","title":"上海医药(601607.SH):雷贝拉唑钠肠溶片通过仿制药一致性评价","url":"https://stock-news.laohu8.com/highlight/detail?id=2426456951","media":"智通财经","top":-1,"share":"https://www.laohu8.com/m/news/2426456951?lang=zh_cn&edition=full","pubTime":"2024-04-10 16:27","pubTimestamp":1712737654,"startTime":"0","endTime":"0","summary":"智通财经APP讯,上海医药(601607.SH)公告,公司全资子公司上海上药信谊药厂有限公司(简称“上药信谊”)收到国家药品监督管理局(以下简称“国家药监局”)颁发的关于雷贝拉唑钠肠溶片的《药品补充申请批准通知书》(通知书编号:2024B01493),该药品通过仿制药一致性评价。据悉,雷贝拉唑钠肠溶片主要用于治疗胃溃疡、十二指肠溃疡、吻合口溃疡、反流性食管炎、卓-艾氏(Zollinger-Ellison)综合征,辅助用于治疗胃溃疡或十二指肠溃疡患者根除幽门螺旋杆菌,由EisaiCo.,Ltd研发,最早于1997年在日本上市。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1100552.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2426684455","title":"上海医药:劳拉西泮片通过仿制药质量和疗效一致性评价","url":"https://stock-news.laohu8.com/highlight/detail?id=2426684455","media":"证券日报","top":-1,"share":"https://www.laohu8.com/m/news/2426684455?lang=zh_cn&edition=full","pubTime":"2024-04-10 15:50","pubTimestamp":1712735446,"startTime":"0","endTime":"0","summary":"4月10日,上海医药发布公告称,近日,公司控股子公司山东信谊制药有限公司收到国家药品监督管理局颁发的关于劳拉西泮片的《药品补充申请批准通知书》(通知书编号:2024B00897),该药品通过仿制药质量和疗效一致性评价。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202404103039260286.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2426660271","title":"上海医药(02607):劳拉西泮片通过仿制药质量和疗效一致性评价","url":"https://stock-news.laohu8.com/highlight/detail?id=2426660271","media":"智通财经网","top":-1,"share":"https://www.laohu8.com/m/news/2426660271?lang=zh_cn&edition=full","pubTime":"2024-04-09 17:49","pubTimestamp":1712656177,"startTime":"0","endTime":"0","summary":"智通财经APP讯,上海医药 发布公告,近日,该公司控股子公司山东信谊制药有限公司收到国家药品监督管理局颁发的关于劳拉西泮片的《药品补充申请批准通知书》,该药品通过仿制药质量和疗效一致性评价。2023年5月,山东信谊就该药品仿制药一致性评价向国家药监局提出申请并获受理。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1100062.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2426150093","title":"上海医药最新公告:控股子公司劳拉西泮片通过仿制药一致性评价","url":"https://stock-news.laohu8.com/highlight/detail?id=2426150093","media":"证券之星","top":-1,"share":"https://www.laohu8.com/m/news/2426150093?lang=zh_cn&edition=full","pubTime":"2024-04-09 17:37","pubTimestamp":1712655466,"startTime":"0","endTime":"0","summary":"上海医药公告,公司控股子公司山东信谊制药有限公司收到国家药监局颁发的关于劳拉西泮片的《药品补充申请批准通知书》,该药品通过仿制药质量和疗效一致性评价。劳拉西泮片主要用于焦虑障碍的治疗或用于缓解焦虑症状及与抑郁症状相关的焦虑的短期治疗。以上内容由证券之星根据公开信息整理,由算法生成,与本站立场无关。证券之星力求但不保证该信息(包括但不限于文字、视频、音频、数据及图表)全部或者部分内容的的准确性、完整性、有效性、及时性等,如存在问题请联系我们。本文为数据整理,不对您构成任何投资建议,投资有风险,请谨慎决策。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024040900030752.shtml","is_publish_highlight":false,"gpt_icon":0},{"id":"2426219157","title":"上海医药(601607.SH):劳拉西泮片通过仿制药一致性评价","url":"https://stock-news.laohu8.com/highlight/detail?id=2426219157","media":"智通财经","top":-1,"share":"https://www.laohu8.com/m/news/2426219157?lang=zh_cn&edition=full","pubTime":"2024-04-09 17:26","pubTimestamp":1712654762,"startTime":"0","endTime":"0","summary":"智通财经APP讯,上海医药 发布公告,近日,公司控股子公司山东信谊制药有限公司收到国家药品监督管理局颁发的关于劳拉西泮片的《药品补充申请批准通知书》,该药品通过仿制药质量和疗效一致性评价。2023年5月,山东信谊就该药品仿制药一致性评价向国家药监局提出申请并获受理。截至本公告日,公司针对该药品的一致性评价已投入直接研发费用约人民币825万元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1100035.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2426159009","title":"上海医药04月09日主力资金流入1077万元 连续3日加仓","url":"https://stock-news.laohu8.com/highlight/detail?id=2426159009","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2426159009?lang=zh_cn&edition=full","pubTime":"2024-04-09 16:16","pubTimestamp":1712650616,"startTime":"0","endTime":"0","summary":"04月09日, 上海医药股价涨3.54%,报收11.10元,成交金额4186万元,换手率0.41%,振幅4.85%,量比0.85。上海医药今日主力资金净流入1077万元,连续3日净流入,上一交易日主力净流入578万元,今日环比增加86.33%。近一年数据显示,该股主力连续3日净流入后,次日上涨概率为30.00%,平均涨幅为1.83%。该股近5个交易日下跌1.77%,主力资金累计净流入2583万元;近20日主力资金累计净流入3546万元,其中净流入天数为11日。该股主力净额占比0.11%,港股市场排名48/2627。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404091617348b0276fe&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404091617348b0276fe&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2425600021","title":"【AH互动】上海医药(02607)涨超7% A股逆向下行 机构料创新药业务迎来收获期","url":"https://stock-news.laohu8.com/highlight/detail?id=2425600021","media":"金吾财讯","top":-1,"share":"https://www.laohu8.com/m/news/2425600021?lang=zh_cn&edition=full","pubTime":"2024-04-08 10:33","pubTimestamp":1712543618,"startTime":"0","endTime":"0","summary":"金吾财讯 | 上海医药 开盘后股价震荡走高,截至发稿,涨7.07%,报10.90港元,成交额1487万港元。A股方面,上海医药跌1.50%,报17.12元人民币。消息面上,华兴证券发布研报指,公司2023年实现年实现营收2630 亿元,同比增长12%;归母净利润37.68亿元,同比下降33%;扣非归母净利润35.96亿元,同比下降16%。","market":"fut","thumbnail":"https://static.szfiu.com/news/20210810/ZDVjZjI4MzkxNjI4NTkwMDQ5NTQ5.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20210810/ZDVjZjI4MzkxNjI4NTkwMDQ5NTQ5.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"1934571","is_publish_highlight":false,"gpt_icon":0},{"id":"2425130398","title":"上海医药(02607)下跌5.02%,报10.6元/股","url":"https://stock-news.laohu8.com/highlight/detail?id=2425130398","media":"金融界","top":-1,"share":"https://www.laohu8.com/m/news/2425130398?lang=zh_cn&edition=full","pubTime":"2024-04-05 10:10","pubTimestamp":1712283029,"startTime":"0","endTime":"0","summary":"4月5日,上海医药(02607)盘中下跌5.02%,截至10:10,报10.6元/股,成交681.7万元。上海医药集团股份有限公司是一家大型医药产业集团,主要业务包括药品研发、生产和销售,以及医疗服务提供。公司在2022年的创新药管线取得了多项阶段性进展,新药管线已有62项,其中创新药50项,改良型新药12项,同时公司在国内外拥有药品生产基地,年产约700个药品品种,20多种剂型,过亿产品达到48个。截至2023年年报,上海医药营业总收入2602.95亿元、净利润37.68亿元。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://hk.jrj.com.cn/2024/04/05101040128746.shtml","is_publish_highlight":false,"gpt_icon":0},{"id":"2425303220","title":"上海医药(02607)股价下跌5.018%,现价港币$10.6","url":"https://stock-news.laohu8.com/highlight/detail?id=2425303220","media":"阿斯达克财经","top":-1,"share":"https://www.laohu8.com/m/news/2425303220?lang=zh_cn&edition=full","pubTime":"2024-04-05 10:10","pubTimestamp":1712283000,"startTime":"0","endTime":"0","summary":"[下跌股]上海医药(02607) 股价在上午10:10比前收市价下跌5.018%,现股价为港币$10.6。至目前为止,今日最高价为$11.16,而最低价为$10.6。总成交量为62.41万股,总成交金额为港币$677.353万。","market":"us","thumbnail":"http://plib.aastocks.com/aafnnews/image/medialib/20180725131625844_s.jpg","type":0,"news_type":0,"thumbnails":["http://plib.aastocks.com/aafnnews/image/medialib/20180725131625844_s.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aamm-content/AAD2404051358/aamm-all-category","is_publish_highlight":false,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.shaphar.com.cn","stockEarnings":[{"period":"1week","weight":-0.0218},{"period":"1month","weight":-0.0723},{"period":"3month","weight":-0.0019},{"period":"6month","weight":-0.0409},{"period":"1year","weight":-0.2784},{"period":"ytd","weight":-0.056}],"compareEarnings":[{"period":"1week","weight":-0.0415},{"period":"1month","weight":-0.0087},{"period":"3month","weight":0.0704},{"period":"6month","weight":-0.0458},{"period":"1year","weight":-0.1955},{"period":"ytd","weight":-0.0388}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"上海医药集团股份有限公司是一家主要从事医药工业、分销与零售业务的中国公司。该公司的产品包括创新药、化学药、中药和罕见病药。该公司的产品主要用于心血管系统、消化道和新陈代谢、全身性抗感染、中枢神经系统、抗肿瘤和免疫调节剂、骨骼肌肉系统和呼吸系统等领域。另外,该公司还提供医药物流和仓储服务。该公司的产品销往中国国内和海外市场。","yearOnYearQuotes":[{"month":1,"riseRate":0.538462,"avgChangeRate":0.004801},{"month":2,"riseRate":0.615385,"avgChangeRate":0.022513},{"month":3,"riseRate":0.615385,"avgChangeRate":0.015446},{"month":4,"riseRate":0.538462,"avgChangeRate":0.000879},{"month":5,"riseRate":0.5,"avgChangeRate":-0.010331},{"month":6,"riseRate":0.461538,"avgChangeRate":-0.014458},{"month":7,"riseRate":0.307692,"avgChangeRate":-0.02229},{"month":8,"riseRate":0.461538,"avgChangeRate":0.012296},{"month":9,"riseRate":0.307692,"avgChangeRate":0.002433},{"month":10,"riseRate":0.307692,"avgChangeRate":-0.017861},{"month":11,"riseRate":0.384615,"avgChangeRate":0.027207},{"month":12,"riseRate":0.615385,"avgChangeRate":-0.010293}],"exchange":"SEHK","name":"上海医药","nameEN":"SH PHARMA"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.22.4","shortVersion":"4.22.4","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"上海医药(02607)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供上海医药(02607)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"上海医药,02607,上海医药股票,上海医药股票老虎,上海医药股票老虎国际,上海医药行情,上海医药股票行情,上海医药股价,上海医药股市,上海医药股票价格,上海医药股票交易,上海医药股票购买,上海医药股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"上海医药(02607)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供上海医药(02607)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}